Antidepressants for neuroprotection in Huntington's disease: A review

European Journal of Pharmacology

Volumn 769, Issue , 2015, Pages 33-42

  Jamwal, Sumit ^a,b   Kumar, Puneet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b I K GUJRAL PUNJAB TECHNICAL UNIVERSITY   (India)

Author keywords

Antidepressants; Brain derivedneurotrophicfactor; Huntingtin protein; Huntington's disease; MAPK ERK signalling; Wnt GSK 3 Signalling

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROPROTECTIVE AGENT;

ANIMAL; HUMAN; HUNTINGTON DISEASE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; HUNTINGTON DISEASE; NEUROPROTECTIVE AGENTS;

EID: 84949106438     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.10.033     Document Type: Review

References (96)

1. H. Aberle, A. Bauer, J. Stappert, A. Kispert, and R. Kemler Beta-Catenin is a target for the ubiquitin-proteasome pathway EMBO J. 16 13 1997 3797 3804
2. A.E. Autry, and L.M. Monteggia Brain-derived neurotrophic factor and neuropsychiatric disorders Pharmacol. Rev. 64 2 2012 238 258
3. T.E. Bayer, M. Schramm, N. Feldmann, M.B. Knable, and P. Falkai Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 24 6 2000 881 888
4. J. Behrens, J.P. von. Kries, M. Kuhl, L. Bruhn, D. Wedlich, R. Grosschedl, and W. Birchmeier Functional interaction of b-catenin with the transcription factor LEF-1 Nature 382 6592 1996 638 642
5. M. Borrell-Pages, D. Zala, S. Humbert, and F. Saudou Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies Cell. Mol. Life Sci. 63 22 2006 2642 2660
6. E. Brouillet, C. Jacquard, N. Bizat, and D. Blum 3-Nitropropionic acid and Malonate: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease J. Neurochem. 95 6 2005 1521 1540
7. J. Butterworth, C.M. Yates, and G.P. Reynolds Distribution of phosphate activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gammaglutamyl transpeptidase in post mortem brain from Huntington's disease and agonal cases J. Neurol. Sci. 67 2 1985 161 171
8. T. Caraceni, G. Calderini, A. Consolazione, E. Riva, S. Algeri, and F. Girotti Biochemical aspects of Huntington's chorea J. Neurol. Neurosurg. Psychiatry 40 6 1977 581 587
9. A. Chairoungdua, D.L. Smith, P. Pochard, M. Hull, and M.J. Caplan Exosome release of b-catenin: a novel mechanism that antagonizes Wnt signalling J. Cell. Biol. 190 6 2010 1079 1091
10. B. Chen, D. Dowlatshahi, G.M. MacQueen, J.-F. Wang, and L.T. Young Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication Biol. Psychiatry 50 4 2001 260 265
11. C.M. Chen Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease Chang Gung Med. J. 34 2 2011 135 152
12. G. Chen, T. Creson, S. Engel, Y. Hao, and G. Wang Neurotrophic actions of mood-stabilizers: a recent research discovery and its potential clinical applications Curr. Psychiatry Rev. 1 2 2005 173 185
13. G. Chen, and H.K. Manji The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers Curr. Opin. Psychiatry 19 3 2006 313 323
14. J.Y. Chen, E.A. Wang, C. Cepeda, and M.S. Levine Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility Front. Neurosci. 7 2013 114
15. T.K. Creson, P. Yuan, H.K. Manji, and G. Chen Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate J. Mol. Neurosci. 37 2 2009 123 134
16. B. Di Benedetto, J. Radecke, M. Schmidt, and R. Rupprecht Acute antidepressant treatment differently modulates ERK/MAPK activation in neurons and astrocytes of the adult mouse prefrontal cortex Neuroscience 232 2013 161 168
17. M. DiFiglia Excitotoxic injury of the neostriatum: a model for Huntington's disease Trends Neurosci. 13 7 1990 286 289
18. Z.R. Donaldson, K.M. Nautiyal, S.E. Ahmari, and R. Hen Genetic approaches for understanding the role of serotonin receptors in mood and behavior Curr. Opin. Neurobiol. 23 3 2013 399 406
19. W. Duan, Q. Peng, N. Masuda, E. Ford, E. Tryggestad, and B. Ladenheim Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease Neurobiol. Dis. 30 3 2008 312 322
20. V. Duric, and R.S. Duman Depression and treatment response: dynamic interplay of signalling pathways and altered neural processes Cell. Mol. Life Sci. 70 1 2013 39 53
21. H.B. Fernandes, K.G. Baimbridge, J. Church, M.R. Hayden, and L.A. Raymond Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease J. Neurosci. 27 50 2007 13614 13623
22. R.M. Friedlander Apoptosis and caspases in neurodegenerative diseases N. Engl. J. Med. 348 14 2003 1365 1375
23. S. Galli, D.M. Lopes, R. Ammari, J. Kopra, S.E. Millar, and A. Gibb Deficient Wnt signalling triggers striatal synaptic degeneration and impaired motor behaviour in adult mice Nat. Commun. 5 2014 4992
24. J.M. Gill, and A.C. Rego Mechanism of neurodegeneration in Huntington's dinase Eur. J. Neurosci. 27 11 2008 2803 2820
25. J.D. Godin, G. Poizat, M.A. Hickey, F. Maschat, and S. Humbert Mutant huntingtin-impaired degradation of β-catenin causes neurotoxicity in Huntington's disease EMBO 29 14 2010 2433 2445
26. M.D. Gordon, and R. Nusse Wnt signalling: multiple pathways, multiple receptors, and multiple transcription factors J. Biol. Chem. 281 32 2006 22429 22433
27. H.E. Grote, N.D. Bull, M.L. Howard, A. Van Dellen, C. Blakemore, and P.F. Bartlett Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine Eur. J. Neurosci. 22 8 2005 2081 2088
28. J.O. Groves Is it time to reassess the BDNF hypothesis of depression? Mol. Psychiatry 12 12 2007 1079 1088
29. S.J. Harrison-Uy, and S.J. Pleasure Wnt signalling and forebrain development Cold Spring Harb. Perspect. Biol. 4 7 2012 a008094
30. A. Hausladen, and I. Fridovich Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not J. Biol. Chem. 269 47 1994 29405 29408
31. J. Hunsberger, D.R. Austin, I.D. Henter, and G. Chen The neurotrophic and neuroprotective effects of psychotropic agents Dialog-Clin. Neurosci. 11 3 2009 333 348
32. C.Y. Janda, D. Waghray, A.M. Levin, C. Thomas, and K.C. Garcia Structural basis of Wnt recognition by Frizzled Science 337 6090 2012 59 64
33. J. Leegwater-Kim, and J.-H.J. Cha The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration NeuroRx 1 1 2004 128 138
34. H. Kalonia, P. Kuamr, B. Nehru, and A. Kumar Neuroprotective Effects of MK-801 against intra-striatal quinolinic acid induced behavioural, oxidative stress and cellular alteration in rats Indian J. Exp. Biol. 47 11 2009 880 892
35. H. Kalonia, P. Kumar, and A. Kumar Attenuation of pro-inflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington's like alteration in rats Brain Res. 1372 2011 115 126
36. H. Kalonia, P. Kumar, and A. Kumar Licofelone attenuates quinolinic acid induced Huntington's like symptoms: possible behavioural, biochemical and cellular alterations Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2 2011 607 615
37. W.Y. Kim, and W.D. Snider Functions of GSK-3β signalling in development of the nervous system Front. Mol. Neurosci. 4 2011 44
38. F. Klempin, H. Babu, D.D.P. Tonelli, E. Alarcon, K. Fabel, and G. Kempermann Oppositional effects of serotonin receptors 5-HT1a, 2, and 2c in the regulation of adult hippocampal neurogenesis Front. Mol. Neurosci. 3 2010 14
39. E. Koponen, T. Rantamäki, V. Voikar, T. Saarelainen, E. MacDonald, and E. Castrén Enhanced BDNF signalling is associated with an antidepressant-like behavioral response and changes in brain monoamines Cell. Mol. Neurobiol. 25 6 2005 973 980
40. S.G. Kornstein, A.F. Schatzberg, M.E. Thase, K.A. Yonkers, J.P. McCullough, and G.I. Keitner Gender differences in treatment response to sertraline versus imipramine in chronic depression Am. J. Psychiatry 157 9 2014 1445 1452
41. P. Kumar, S. Padi, P. Naidu, and K. Anil Protective effects of antioxidants on 3-NP induced oxidative stress and cognitive impairment Anna. Neurosci. 13 2 2006 41 47
42. P. Kumar, S. Padi, P. Naidu, and A. Kumar Effects of resveratrol on 3-NP induced neurotoxicity, an animal model of Huntington's disease: possible neuroprotective mechanism Behav. Pharm. 17 5-6 2007 485 492
43. P. Kumar, S. Padi, P. Naidu, and A. Kumar Possible neuroprotective mechanism of curcumin in attenuating 3-NP acid induced neurotoxicity Methods Find. Exp. Clin. Pharmacol. 29 1 2007 19 25
44. P. Kumar, H. Kalonia, and A. Kumar Sesamol attenuates 3- Nitropropionic Acid induced Huntington like behaviour, biochemical and cellular alterations in rats J. Asian Nat. Prod. Res. 11 5 2009 439 450
45. P. Kumar, H. Kalonia, and A. Kumar Lycopene modulates nitric oxide pathways against-Nitropropionic Acid induced neurotoxicity Life Sci. 85 19-20 2009 711 718
46. P. Kumar, and A. Kumar Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain Prog. Neuropsychopharmacol. Biol. Psychiatry 33 1 2009 100 108
47. P. Kumar, and A. Kumar Protective role of sertraline against 3-Nitropropionic Acid induced cognitive dysfunction and redox ratio in striatum, cortex and hippocampus of rat brain Indian J. Exp. Biol. 47 9 2009 715 722
48. P. Kumar, H. Kalonia, and A. Kumar Nitric oxide mechanism in the protective effects of antidepressants against 3-Nitropropionic acid induced cognitive deficit, glutathione and mitochondrial alteration in animal model of Huntington's disease Behav. Pharmacol. 21 3 2010 217 230
49. P. Kumar, H. Kalonia, and A. Kumar Novel protective mechanisms of antidepressants against 3-nitroproprionic acid induced Huntington's-like symptoms: a comparative study J. Psychopharmacol. 25 10 2011 1399 1411
50. P. Kumar, H. Kalonia, and A. Kumar Role of LOX/COX pathways in 3-Nitropropionic acid induced HD like symptoms in rats: protective role of lycofelone Br. J. Pharmacol. 164 2b 2011 644 654
51. E.C. Lauterbach Neuroprotective effects of psychotropic drugs in Huntington's disease Int. J. Mol. Sci. 14 11 2013 22558 22603
52. S.-H. Li, S. Lam, A.L. Cheng, and X.-J. Li Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis Hum. Mol. Genet. 9 19 2000 2859 2867
53. M.T. Lin, and M.F. Beal Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 443 7113 2006 787 795
54. J.E. Malberg, A.J. Eisch, E.J. Nestler, and R.S. Duman Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus J. Neurosci. 20 24 2000 9104 9110
55. G. Mercier, A.M. Lennon, B. Renouf, A. Dessouroux, M. Ramaugé, F. Courtin, and M. Pierre MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes J. Mol. Neurosci. 24 2 2004 207 216
56. B.H. Miller, L.E. Schultz, A. Gulati, M.D. Cameron, and M.T. Pletcher Genetic regulation of behavioral and neuronal responses to fluoxetine Neuropsychopharmacology 33 6 2008 1312 1322
57. L.M. Monteggia, M. Barrot, C.M. Powell, O. Berton, V. Galanis, T. Gemelli, S. Meuth, and et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function Proc. Natl. Acad. Sci. USA 101 29 2004 10827 10832
58. L.M. Monteggia, B. Luikart, M. Barrot, D. Theobold, I. Malkovska, S. Nef, L.F. Parada, and et al. Brain-Derived neurotrophic factor conditional knock outs show gender differences in depression related behaviors Biol. Psychiatry 61 2 2007 187 197
59. R. Mostany A role for nuclear beta-catenin in SNRI antidepressant-induced hippocampal cell proliferation Neuropharmacology 55 1 2008 18 26
60. M. Nibuya, E.J. Nestler, and R.S. Duman Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus J. Neurosci. 16 7 1996 2365 2372
61. H.S. Pan, and R.Y. Wang MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system Brain Res. 539 2 1991 332 336
62. T.Y. Pang, X. Du, M.S. Zajac, M.L. Howard, and A.J. Hannan Altered serotonin receptor expression is associated with depression related behavior in the R6/1 transgenic mouse model of Huntington's disease Hum. Mol. Genet. 18 4 2009 753 766
63. Q. Peng, N. Masuda, M. Jiang, Q. Li, M. Zhao, C.A. Ross, and W. Duan The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2Huntington's disease mouse model Exp. Neurol. 210 1 2008 154 163
64. F. Pilar-Cuéllar, R. Vidal, and A. Pazos Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, -catenin and antidepressant-like effects Br. J. Pharmacol. 165 4b 2012 1046 1057
65. P. Pla, S. Orvoen, F. Saudou, D.J. David, and S. Humbert Mood disorders in Huntington Disease: from behaviour to cellular and molecular mechanism Front. Behav. Neurosci. 8 2014 135
66. T. Pringsheim, K. Wiltshire, L. Day, J. Dykeman, T. Steeves, and N. Jette The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis Mov Disord 27 9 2012 1083 1091
67. Przedborski, S., 2007. Neuroinflammation and Parkinson's disease. In: Vinken, P.J., Bruyn, G.W., (Eds), Handb Clin Neurol. 83, pp. 535-551.
68. T. Rantamaki, P. Hendolin, A. Kankaanpaa, J. Mijatovic, P. Piepponen, E. Domenici, M.V. Chao, and et al. Pharmacologically diverse antidepressants rapidly activate brain derived neurotrophic factor receptor TrkB and induce phospholipase-C gamma signalling pathways in mouse brain Neuropsychopharmacology 32 10 2007 2152 2162
69. W. Reedeker, R. van der Mast, E. Giltay, T. Kooistra, R. Roos, and E. van Duijn Psychiatric disorders in Huntington's disease: a 2-year follow up study Psychosomatics 53 3 2012 220 229
70. T. Renoir, M.S. Zajac, X. Du, T.Y. Pang, L. Leang, C. Chevarin, L. Lanfumey, and et al. Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's Disease and depression PLoS One 6 7 2011 e22133
71. T. Renoir, T.Y. Pang, M.S. Zajac, G. Chan, X. Du, L. Leang, C. Chevarin, and et al. Treatment of depressive like behaviour in Huntington's disease mice by chronic sertraline and exercise Br. J. Pharmacol. 165 5 2012 1375 1389
72. A. Riccio, S. Ahn, C.M. Davenport, J.A. Blendy, and D.D. Ginty Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons Science 286 5448 1999 2358 2361
73. G. Richards, J. Messer, H.J. Waldvogel, H.M. Gibbons, M. Dragunow, R.L. Faull, and J. Saura Upregulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography Brain Res. 1370 2011 204 214
74. T. Saarelainen, P. Hendolin, G. Lucas, E. Koponen, M. Sairanen, E. MacDonald, K. Agerman, and et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant induced behavioral effects J. Neurosci. 23 1 2003 349 357
75. C. Sackley, T.J. Hoppitt, M. Calvert, P. Gill, B. Eaton, G. Yao, and H. Pall Huntington's disease: current epidemiology and pharmacological management in UK primary care Neuroepidemiology 37 3-4 2011 216 221
76. P.C. Salinas Wnt signalling in the vertebrate central nervous system: from axon guidance to synaptic function. Cold Spring Harb Perspect Biology 4 2 2012 a008003
77. F. Saudou, S. Finkbeiner, D. Devys, and M.E. Greenberg Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95 1 1998 55 66
78. Y. Shirayama, A.C.-H. Chen, S. Nakagawa, D.S. Russell, and R.S. Duman Brain derived neurotrophic factor produces antidepressant effects in behavioral models of depression J. Neurosci. 22 8 2002 3251 3261
79. A. Silvestroni, R.L. Faull, A.D. Strand, and T. Möller Distinct neuroinflammatory profile in post-mortem human Huntington's disease Neuroreport 20 12 2009 1098 1103
80. J.A. Siuciak, D.R. Lewis, S.J. Wiegand, and R.M. Lindsay Antidepressant-like effects of brain-derived neurotrophic factor (BDNF) Pharmacol. Biochem. Behav. 56 1 1997 131 137
81. B. Su, X. Wang, L. Zheng, G. Perry, M.A. Smith, and X. Zhu Abnormal mitochondrial dynamics and neurodegenerative diseases Biochem. Biophys. Acta 1802 1 2010 135 142
82. S. Tabrizi, M. Cleeter, J. Xuereb, J.W. Taanman, J. Cooper, and A. Schapira Biochemical abnormalities and excitotoxicity in Huntington's disease brain Ann. Neurol. 45 1 1999 25 32
83. T.-S. Tang, E. Slow, V. Lupu, I.G. Stavrovskaya, M. Sugimori, R. Llinás, B.S. Kristal, and et al. Disturbed Ca2+ signalling and apoptosis of medium spiny neurons in Huntington's disease Proc. Natl. Acad. Sci. USA 102 7 2005 2602 2607
84. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism Neuron 20 4 1998 709 726
85. A.M. Van Dongen, H.B. Fernandes, and L.A. Raymond Biology of the NMDA Receptor A.M. Van Dongen, Boca Raton (FL) 2008 CRC Press 2008
86. C. Wellington, B.R. Leavitt, and M.R. Hayden Huntington disease: new insights on the role of huntingtin cleavage Y. Mizuno, D.B. Calne, R. Horowski, W. Poewe, P. Riederer, M.B.H. Youdim, Advances in Research on Neurodegeneration 2000 Springer Vienna 1 17
87. C. Wellington, B. Leavitt, and M. Hayden Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease J. Neurosci. 22 18 2002 7862 7872
88. K. Willert, and R. Nusse Wnt proteins. Cold Spring Harb Perspect. Biol. 4 9 2012 a007864
89. E.H. Wong, G.P. Reynolds, D.W. Bonhaus, S. Hsu, and R.M. Eglen Characterization of 3HGR113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders Behav. Brain Res. 73 1 1995 249 252
90. M. Zajac, T. Pang, N. Wong, B. Weinrich, L. Leang, J. Craig, R. Saffery, and A. Hannan Wheel running and environmental enrichment differentially modify exon specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice Hippocampus 20 5 2010 621 636
91. S. Zeitlin, J.-P. Liu, D.L. Chapman, V.E. Papaioannou, and A. Efstratiadis Increased apoptosis and early embryonic lethality in mice nullizygous for huntington's disease gene homologue Nat. Genet. 11 2 1995 155 163
92. M.M. Zeron, N. Chen, A. Moshaver, A.T.-C. Lee, C.L. Wellington, M.R. Hayden, and L.A. Raymond Mutant huntingtin enhances excitotoxic cell death Mol. Cell. Neurosci. 17 1 2001 41 53
93. M.M. Zeron, O. Hansson, N. Chen, C.L. Wellington, B.R. Leavitt, P. Brundin, M.R. Hayden, and et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease Neuron 33 6 2002 849 860
94. L. Zhang, X. Yang, S. Yang, and J. Zhang The Wnt/b-catenin signalling pathway in the adult neurogenesis Eur. J. Neurosci. B 33 1 2011 1 8
95. C. Zuccato, and E. Cattaneo Brain derived neurotrophic factor in neurodegenerative diseases Nat. Rev. Neurol. 5 6 2009 311 322
96. C. Zuccato, M. Marullo, B. Vitali, A. Tarditi, C. Mariotti, M. Valenza, N. Lahiri, and et al. Brain-derived neurotrophic factor in patients with Huntington's disease PLoS One 6 8 2011 e22